Mead Johnson Welcomes Defense Verdict in Inman Case
Mead Johnson Welcomes Defense Verdict in Inman Case
Mead Johnson welcomes today’s unanimous jury verdict in the company's favor in the Inman case in the U.S. District Court for the Northern District of Illinois. This was the first bellwether case against Mead Johnson tried in the federal Multi-District Litigation (MDL) involving allegations concerning the cause of necrotizing enterocolitis (NEC), a serious gastrointestinal condition that primarily affects premature infants. With this decision, there are currently no outstanding jury verdicts in the overall NEC litigation against Mead Johnson, as juries in the state cases Collins and Whitfield ruled in our favor and the Illinois Appellate Court reversed the Watson decision.
For over 120 years, Mead Johnson has been dedicated to supporting the healthy development of babies through our science-backed pediatric nutrition products, and we continue to offer our deepest condolences to Ms. Inman and her family.
Today’s verdict affirms Mead Johnson’s view that the science doesn’t support the claims here or in the litigation more broadly. We strongly reject any assertion that any of our products cause NEC, and we will continue to vigorously defend ourselves against all such claims in the interest of safeguarding the health of premature babies.
Specialized preterm hospital nutrition products provide essential, lifesaving nutrition to the most vulnerable infants when mother’s or donor milk is unavailable or insufficient. Mead Johnson is committed to innovation that supports even the most complex of dietary needs for all babies. We stand behind the safety and efficacy of our specialized preterm hospital nutrition products, which neonatologists recommend when clinically appropriate as part of the standard of care in neonatal intensive care units.
For more information on Mead Johnson’s specialized preterm hospital nutrition products and the NEC litigation, see here: https://www.pretermnutritionlitigation.com/.
Nick Ashworth
Investor Relations
+44 (0)7408 812350
ir@reckitt.com
Jennifer O'Neill
Communications and Corporate Affairs
+1 (917) 721-8354
media&pr@reckitt.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260831302140/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The 10 Best Companies to Invest in Now
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
3 Stocks to Sell and 3 Stocks to Buy for October
The Top Funds for a Simpler Retirement Portfolio
United States